Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis
Primary Purpose
Cystic Fibrosis
Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Hypertonic Saline
Sponsored by
About this trial
This is an interventional diagnostic trial for Cystic Fibrosis focused on measuring Pediatrics, Cystic Fibrosis, Hypertonic Saline, Induced Sputum, Expectorated Sputum
Eligibility Criteria
Inclusion Criteria:
- Children diagnosed with CF (by sweat chloride ≥60 and/or genetic testing)
- Children ages between 6-18 years
- Ability to perform pulmonary function tests
- FEV1 ≥ 30% predicted18.
Additional inclusion criteria for sub-sample undergoing antibiotic therapy:
- Above criteria
- Admitted to hospital for i.v. antibiotic therapy
Exclusion Criteria:
- Acute respiratory distress or hypoxia (oxygen saturation <92% at room air)
- New onset of wheezing
- Previous history of intolerance of inhalation of HS
Sites / Locations
- The Hospital for Sick Children
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
1
Arm Description
Outcomes
Primary Outcome Measures
Additional positive bacterial culture yield post IS technique for known and emerging CF pathogens over conventional methods of bacterial culturing (ES and TS).
Secondary Outcome Measures
Inflammatory profile as measured by relative neutrophil count and IL-8 concentration in the IS
Bacterial colony counts
Frequency of change in clinical management based on results from IS
Full Information
NCT ID
NCT00721071
First Posted
July 21, 2008
Last Updated
August 30, 2013
Sponsor
The Hospital for Sick Children
1. Study Identification
Unique Protocol Identification Number
NCT00721071
Brief Title
Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis
Official Title
Diagnostic Utility of Induced Sputum Using Hypertonic Saline to Evaluate Airway Infection and Inflammation in Cystic Fibrosis
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
December 2006 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
May 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Hospital for Sick Children
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of the study is to evaluate the clinical utility and the feasibility, in an outpatient setting, of sputum induction using hypertonic saline. This study will also study pilot techniques on a sub using a sub-sample to assess the lower airway inflammatory cells and markers in relation to new emerging organisms in cystic fibrosis (CF) and antibiotic therapy in CF.
Detailed Description
Chronic airway infection, mainly by Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA), is a major cause of morbidity and mortality in patients with cystic fibrosis (CF). Isolation of organisms from the respiratory tract is important to optimize treatment. The current recommended methods for bacterial evaluation are bronchoalveolar lavage (BAL) and expectorated sputum (ES) analysis. However, a significant proportion of young CF patients cannot produce sputum spontaneously. The method used most frequently therefore is to isolate respiratory organisms is to perform throat swabs (TS) which have poor sensitivity and specificity in the evaluation of respiratory pathogens in CF patients.
Induced sputum (IS) using hypertonic saline has been used in a limited number of studies to evaluate respiratory organisms in CF patients. These studies have reported that IS may be a useful non-invasive diagnostic test to increase the yield of detection of respiratory pathogens.
Beside its use as a diagnostic test to identify bacterial pathogens induced sputum has been used to assess lower airway inflammation in CF. While numerous studies have clarified the role of S. aureus and P. aeruginosa in CF lung disease, the role of other emerging bacteria such as Stenotrophomonas maltophilia (SM) and Achromobacter xylosoxidans (AX) species remains largely unclear. IS offers the potential to possibly differentiate between colonisation and infection for the emerging pathogens and to help clarify their role in CF lung disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis
Keywords
Pediatrics, Cystic Fibrosis, Hypertonic Saline, Induced Sputum, Expectorated Sputum
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
95 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Hypertonic Saline
Intervention Description
After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
Primary Outcome Measure Information:
Title
Additional positive bacterial culture yield post IS technique for known and emerging CF pathogens over conventional methods of bacterial culturing (ES and TS).
Time Frame
60 minutes; for subgroup, this will be repeated a second time after 14 days.
Secondary Outcome Measure Information:
Title
Inflammatory profile as measured by relative neutrophil count and IL-8 concentration in the IS
Time Frame
60 minutes; for subgroup, this will be repeated a second time after 14 days.
Title
Bacterial colony counts
Time Frame
60 minutes; for subgroup, this will be repeated a second time after 14 days.
Title
Frequency of change in clinical management based on results from IS
Time Frame
60 minutes; for subgroup, this will be repeated a second time after 14 days.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Children diagnosed with CF (by sweat chloride ≥60 and/or genetic testing)
Children ages between 6-18 years
Ability to perform pulmonary function tests
FEV1 ≥ 30% predicted18.
Additional inclusion criteria for sub-sample undergoing antibiotic therapy:
Above criteria
Admitted to hospital for i.v. antibiotic therapy
Exclusion Criteria:
Acute respiratory distress or hypoxia (oxygen saturation <92% at room air)
New onset of wheezing
Previous history of intolerance of inhalation of HS
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Felix Ratjen, MD
Organizational Affiliation
The Hospital for Sick Children, Toronto Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Hospital for Sick Children
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X8
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
20630539
Citation
Al-Saleh S, Dell SD, Grasemann H, Yau YC, Waters V, Martin S, Ratjen F. Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr. 2010 Dec;157(6):1006-1011.e1. doi: 10.1016/j.jpeds.2010.06.001. Epub 2010 Jul 14.
Results Reference
result
Learn more about this trial
Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis
We'll reach out to this number within 24 hrs